Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/23/21 | $72,000,000 | Series A |
Aisling Capital Mass General Brigham Ventures Monashee Investment Management Northpond Ventures OrbiMed Advisors Resilience Capital Partners Ridgeback Capital Management Sectoral Asset Management | undisclosed |
| 02/07/23 | $62,000,000 | Series B |
Aisling Capital Alexandria Venture Investments Cormorant Asset Management Mass General Brigham Ventures Northpond Ventures OrbiMed Advisors Sectoral Asset Management | undisclosed |
